A Phase 2 interventional study of Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine and Docetaxel + gemcitabine + carboplatin + radiotherapy in Lung Neoplasms, sponsored by Sanofi. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-07.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing docetaxel in Lung Neoplasms — 1 open to participants now, 3 under way, 1 of them phase 3. Docetaxel · Lung Neoplasms.
Among the 100 studies testing docetaxel in Lung Neoplasms, this one is the 15th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2001, is one of 68 in phase 2, and was the 47th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →1 of the 100 studies testing docetaxel in Lung Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 76 · Phase 3 12 · Phase 4 1
First in 1996; this study’s year is marked. 9 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 46 across the 90 interventional studies. Of the 78 that completed or were terminated, 20 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 100 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
23 studies in Lung Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 21 finished, 5 (24%) have results posted.
Among the 23 studies in Lung Neoplasms by Sanofi, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 2, and was the 5th registered.
Sanofi’s Lung Neoplasms studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 100 studies testing docetaxel in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 23 in Lung Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
Secondary objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
Drug: Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
Other: Docetaxel + gemcitabine + carboplatin + radiotherapy
Drug pages: Docetaxel · Carboplatin · Gemcitabine
Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
Response rate in each arm measured according to RECIST criteria
Time frame: Throughout the whole study
Percentage of local-regional control within a year
Time frame: Throughout the first year
Time to progression defined as the period of time elapsed between the randomization date and the progression or death date
Time frame: Throughout the whole study
Toxicity measured by CALGB criteria and RTOG/EORTC criteria
Time frame: Throughout the whole study
Global surveillance measured as the period of time elapsed between randomization and death date.
Time frame: Throughout the whole study duration
The record gives a start of Oct 2001 and a primary completion of Sep 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Carboplatin · Gemcitabine